Generalsuche Home Home mobil Mobil Help Hilfe Sitemap Sitemap Kontakt Kontakt Impressum Impressum Datenschutz Datenschutz RSS Feed Feeds
News / Newsletter
Veranstaltungen / Events
Publikationen / E-Library
Web-Ressourcen
AMS/ABI-BerufsInfoRessourcen
AMS/ABI-BerufsInfoService
AMS/ABI Newsletter
Forschungseinrichtungen
Forschungsdatenbanken
Forschungsnetzwerke
Internationale Organisationen
Online Zeitschriften
Quinora
Arbeitsmarktstatistik
Weitere Statistik-Ressourcen
AMS-JobBarometer
Jobchancen Studium
Merkliste Merkliste News
Merkliste Merkliste Events
Merkliste Merkliste E-Library
Merkliste Merkliste Jobch. News
Merkliste Merkliste Methoden
 
Detailansicht E-LibraryKurztipp   
zurück Suchergebnisse  
  Merkliste bearbeiten / via E-Mail sendenTitel merken  
VerfasserInnen / HerausgeberInnen
AutorIn 1:PWC
HerausgeberIn 1:PricewaterhouseCoopers
Titel
Titel:Biotech reinvented. Where do you go from here?
Untertitel:Pharmaceuticals and Life Sciences
Veröffentlichungsvermerk
Verlag:PricewaterhouseCoopers
Jahr:2010
Abstract
Abstract:"(...) The biotechnology industry (Biotech) is now about 30 years old - a long enough time in which to evaluate how it?s done. Unfortunately, despite some notable successes, it hasn?t completely fulfilled its promise. The business model on which Biotech has historically relied is also breaking down, as the research base moves east and raising funds gets harder. And the distinctions between Biotech and the pharmaceutical industry (Pharma) are disappearing, with the convergence of the two sectors. But Biotech can?t turn to Pharma for guidance because Pharma?s business model has other flaws - as we explained in "Pharma 2020: Challenging business models?, the White Paper we published in April 2009.1 So what should Biotech do? We believe it should capitalise on the opportunities emerging in the healthcare arena - and reinvent itself by adopting a more collaborative approach. In the following pages, we?ll look at the main trends dictating the need for a new way of conducting Research and development (R&D), and two organisational concepts that would help biopharmaceutical companies become far more efficient. We?ll also touch on the implications for other parts of the value chain. (...)"
[Foresight]
Verfügbarkeit
Download: hier klicken (PDF  497 KB)
URL: PricewaterhouseCoopers